Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub
Opioid analgesic combination/Discontinued

PROPACET 100

PROPACET 100

Clinical safety rating

caution

Comprehensive clinical and safety monograph for PROPACET 100 (PROPACET 100).


Mechanism of Action

Propacet 100 is a prodrug of acetaminophen; it is hydrolyzed to acetaminophen, which inhibits cyclooxygenase (COX) and modulates the endogenous cannabinoid system, leading to analgesic and antipyretic effects.

What the body does with it

MetabolismRapidly hydrolyzed by plasma esterases to acetaminophen; acetaminophen is primarily metabolized by glucuronidation and sulfation, with a minor pathway via CYP2E1 to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI).
ExcretionPropacet 100 (propacetamol) is a prodrug of acetaminophen. Renal elimination accounts for >90% of the administered dose, with approximately 85% as acetaminophen glucuronide and sulfate conjugates, and about 5% as unchanged acetaminophen. Biliary/fecal elimination is minimal (<5%).
Half-lifeThe terminal elimination half-life of acetaminophen after propacetamol administration is approximately 2–3 hours in adults with normal hepatic function. This half-life may be prolonged in patients with hepatic impairment or overdose.
Protein bindingAcetaminophen is minimally bound to plasma proteins, with protein binding of approximately 10–25% at therapeutic concentrations. It binds primarily to albumin.
Volume of DistributionThe volume of distribution (Vd) of acetaminophen is approximately 0.9–1.0 L/kg, indicating distribution into total body water. This reflects its hydrophilic nature and widespread tissue penetration.
BioavailabilityPropacetamol is administered intravenously; thus, bioavailability is 100%. After hydrolysis to acetaminophen, the bioavailability of active acetaminophen is essentially complete.
Onset of ActionIntravenous administration: Onset of analgesia occurs within 5–10 minutes after the start of infusion. Peak effect is observed at approximately 1 hour.
Duration of ActionDuration of analgesia is approximately 4–6 hours following intravenous administration. Clinical effect correlates with plasma acetaminophen concentrations above therapeutic threshold.
Molecular Weight151.16

Classification & Brands

Dosing & administration

1-2 tablets (100-200 mg propacetamol) orally every 4-6 hours; maximum 8 tablets (800 mg) per day.

Dosage formTABLET
Renal impairmentGFR 30-50 mL/min: extend interval to every 8 hours; GFR <30 mL/min: extend interval to every 12 hours; hemodialysis: dose post-dialysis.
Liver impairmentChild-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: use alternative analgesic.
Pediatric use10-15 mg/kg/dose propacetamol equivalent every 6 hours; maximum 60 mg/kg/day; do not exceed adult dose.
Geriatric useInitiate at lower end of dosing range (100 mg every 6 hours); maximum 800 mg/day; monitor renal and hepatic function.

Use during pregnancy

1st trimesterAvoid. Epidemiologic studies suggest an increased risk of miscarriage and congenital malformations (cardiac, orofacial clefts) with first trimester exposure.
2nd trimesterUse with caution. Potential for oligohydramnios and fetal renal impairment with prolonged use; avoid higher doses and long-term therapy.
3rd trimesterAvoid. Associated with premature closure of the ductus arteriosus, oligohydramnios, and neonatal renal impairment; may inhibit labor and increase risk of periventricular hemorrhage.

Clinical note

Comprehensive clinical and safety monograph for PROPACET 100 (PROPACET 100).

Placental transferTransfers across placenta; fetal serum concentrations may approach maternal levels.
BreastfeedingExcreted into breast milk in low amounts; however, because of potential adverse effects in the infant (e.g., Reye syndrome, Kernicterus), caution is advised; consider alternative analgesics, particularly in G6PD deficiency or if infant is < 3 months old.
Lactation RatingL2 (Safer) when used at recommended doses, but avoid prolonged high-dose therapy.
Teratogenic RiskPropacet 100 (propacetamol) is a prodrug of paracetamol (acetaminophen). First trimester: Limited human data, no increased risk of major malformations in large cohort studies. Second and third trimesters: No known fetal toxicity at therapeutic doses; overdose may cause hepatic necrosis in mother and potentially fetus.
Fetal MonitoringMonitor maternal liver function tests (ALT, AST) if prolonged use or overdose suspected. For chronic or high-dose use, assess fetal growth via ultrasound. No specific fetal monitoring required for short-term therapeutic doses.
Fertility EffectsNo known adverse effects on human fertility. Animal studies show no impairment of fertility at clinical doses.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning exists for propacetamol specifically; however, acetaminophen (active metabolite) carries a risk of severe liver injury in cases of overdose, particularly with chronic alcohol use or hepatic impairment.

Side Effect Profile

Serious Effects

Absolute Contraindications

Severe hepatic impairment or active liver diseaseHypersensitivity to propacetamol or other NSAIDs (aspirin-sensitive asthma)Third trimester of pregnancySevere renal impairment (eGFR <30 mL/min)Active peptic ulcer disease or gastrointestinal bleeding

Clinical Precautions

PrecautionsHepatotoxicity risk with overdose or chronic alcohol use; severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) reported rarely; use with caution in hepatic impairment, alcohol use disorder, or malnutrition.
Food/DietaryNo specific food interactions; however, maintain adequate caloric intake to support glutathione synthesis. Avoid alcohol as it may increase hepatotoxicity risk.

Clinical Tips & Counseling

Clinical PearlsPropacet 100 (propacetamol, a prodrug of acetaminophen) is administered intravenously; ensure patency of IV line to prevent extravasation, which can cause injection site reactions. Contraindicated in severe hepatic impairment (Child-Pugh C) and in patients with glutathione depletion (e.g., malnutrition, sepsis). Monitor liver function tests during prolonged use. Use with caution in patients with asthma, as sulfite in formulation may trigger bronchospasm.
Patient AdvicePropacet 100 is given intravenously for pain or fever; you must receive it in a healthcare setting. · Report any signs of allergic reaction such as rash, itching, swelling, or trouble breathing immediately. · This medication is a prodrug of acetaminophen; do not take additional acetaminophen-containing products while on this therapy. · Avoid alcohol during treatment to reduce risk of liver damage.

PROPACET 100 Interactions

Loading safety data…

This overview is compiled from peer-reviewed clinical sources and FDA labeling. It's here to support — not replace — clinical judgment. Always verify dosing against your institution's current protocols before prescribing.

On this page

Mechanism of ActionDosing & administrationUse during pregnancyWarnings & precautionsDrug interactions

Compare with

ANEXSIAANEXSIA 5/325ANEXSIA 7.5/325ANEXSIA 7.5/650ATROPINE AND DEMEROL

External sources

DailyMed (NIH) PubMed OpenFDA